CARB-X today announced an award of up to $6.8 million to Pattern Bioscience of Austin, Texas, to develop a rapid identification and antimicrobial susceptibility test (ID/AST) for drug-resistant pathogens.
Imperial College London announced yesterday that it has won a €22.5 million ($25 million US) grant to work with researchers in 15 countries over 5 years to develop a rapid test to diagnose infectious diseases based on personalized gene signatures after taking the next 2 years to develop a library of gene signatures covering common infections and other diseases.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $1.5 million to Phase Genomics of Seattle, Washington, to develop a low-cost, culture-free platform for detecting antimicrobial resistance (AMR) genes.
Yesterday, French diagnostics company bioMerieux announced that that the Fleming Fund has selected it as a supplier in a tender process to tackle antimicrobial resistance (AMR) in 18 low- and middle-income countries.
New research by a team of scientists from the United Kingdom suggests that whole-genome sequencing (WGS) should be considered as an alternative to traditional phenotypic testing for national surveillance of antibiotic resistance.
Global funding has reached an all-time high but falls far short of what's needed to eliminate TB.
The US Food and Drug Administration (FDA) today approved a new test to diagnose methicillin-resistant Staphylococcus aureus (MRSA), which will allow health workers to screen patients for MRSA colonization more quickly—in as little as 5 hours compared with 24 to 48 hours for traditional culture-based tests.
Scientists from Harvard University and the Massachusetts Institute of Technology report that a diagnostic test they developed allows simultaneous detection of genotype and phenotype, enabling rapid and accurate antibiotic susceptibility determination in under 4 hours, according to their findings detailed in a letter in Nature Medicine.
The European Public Health Alliance's Stakeholder Network on Antimicrobial Resistance (AMR) has released a roadmap outlining the path European leaders should take in their efforts to fight drug-resistant infections.
Emphasizing the need for a multidisciplinary, "One Health" approach, the roadmap calls for European Union (EU) member states and institutions to pursue five strategies against AMR:
The results of a randomized clinical trial show that the use of a rapid, multi-pathogen respiratory panel (RP) in an emergency department (ED) was associated with a trend toward decreased antibiotic use, according to a study yesterday in Open Forum Infectious Diseases.
